Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) EBIT Margin: 2013-2025

Historic EBIT Margin for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to -472.35%.

  • Ocular Therapeutix's EBIT Margin fell 17414.00% to -472.35% in Q3 2025 from the same period last year, while for Sep 2025 it was -449.66%, marking a year-over-year decrease of 21975.00%. This contributed to the annual value of -269.57% for FY2024, which is 12861.00% down from last year.
  • According to the latest figures from Q3 2025, Ocular Therapeutix's EBIT Margin is -472.35%, which was up 6.01% from -502.57% recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's EBIT Margin ranged from a high of -127.41% in Q3 2023 and a low of -597.47% during Q1 2025.
  • For the 3-year period, Ocular Therapeutix's EBIT Margin averaged around -292.07%, with its median value being -265.13% (2024).
  • As far as peak fluctuations go, Ocular Therapeutix's EBIT Margin skyrocketed by 96,719bps in 2021, and later crashed by 38,346bps in 2025.
  • Ocular Therapeutix's EBIT Margin (Quarterly) stood at -146.64% in 2021, then soared by 909bps to -137.56% in 2022, then spiked by 209bps to -135.46% in 2023, then slumped by 16,061bps to -296.08% in 2024, then plummeted by 17,414bps to -472.35% in 2025.
  • Its EBIT Margin was -472.35% in Q3 2025, compared to -502.57% in Q2 2025 and -597.47% in Q1 2025.